Oral Dosing Articles & Analysis
24 news found
According to the publication, low-dose AD04 did not significantly change biochemical markers of liver injury, such as ALT, AST, and Serum Bilirubin. Additionally, while patients with AUD displayed elevated GGT levels, typically associated with increased alcohol consumption, this parameter remained unaffected by low-dose AD04. Additionally, no significant adverse ...
” Of the multitude of medications available for the more than 17 million child, adolescent, and adult patients in the U.S. living with ADHD, no currently available medications offer a single oral dose that provides patients entire active-day efficacy. This Phase 3 trial is being conducted in an Adult Laboratory Setting (ALS) which has been used extensively ...
(“Inversago”), a clinical stage biotech company with a unique portfolio of peripherally-acting CB1 inverse agonists, today announced that the first patient has been dosed with INV-202 in a Phase 2 clinical trial in subjects with diabetic kidney disease (DKD). ...
The Phase 1 study met all of its primary and secondary endpoints; in all subjects dosed with STAR-LLD, the plasma lenalidomide concentration (AUC) was 57% lower with STAR-LLD continuous subcutaneous (SC) delivery compared to once-daily Revlimid oral delivery. ...
Rani Therapeutics Holdings, Inc. recently announced the development of a high-capacity oral biologics device known as the RaniPill HC (High Capacity), capable of delivering up to a 500%-plus higher drug payload than Rani’s existing oral biologics capsule. ...
Eight subjects in the first two cohorts received 24 hours of STAR-LLD continuous lenalidomide, and a single oral dose of lenalidomide after a 24 hour washout period. “The Phase 1 study evaluated STAR-LLD bioavailability, safety, and pharmacokinetics,” said Jamie Oliver. ...
The AURORA 2 study assessed long-term safety and tolerability of voclosporin compared to placebo (both taken in combination with mycophenolate mofetil (MMF) and low-dose oral steroids) in patients with LN receiving treatment for an additional 24 months following completion of one year on treatment in the AURORA 1 study. ...
In particular, there was a marked, dose-dependent reduction in albuminuria in this model of diabetes and associated kidney injury. ...
In addition, funds will support the expansion of Locus’ discovery platform engine and enhancement of its in-house manufacturing capability to support oral solid dose delivery of its products. “Locus’ novel scientific approach has the potential to fundamentally change the way bacterial diseases are treated. ...
Four subjects in the first cohort received 24 hours of STAR-LLD continuous lenalidomide, and a single oral dose of lenalidomide after a 24 hour washout period. The Independent Data Monitoring Committee reviewed the totality of the safety data from the first cohort and recommended advancement to Part B, where subjects will receive the second-highest of three ...
The latest data, reported on 17 March 2022, demonstrated that BIT225 protected against COVID related death in K18 transgenic mice (a strain generated to be infectable with SARS-CoV-2, resulting in severe COVID) that were infected with a lethal dose of the virus. Control mice that were not dosed with BIT225 all died by Day 8 post-infection with SARS-CoV-2 from ...
Jubilant Therapeutics Inc’s drug discovery platform created a number of lead molecules with b in vitro potency and high selectivity to PAD4 compared to PAD1, PAD2 or PAD3. Oral dosing with a mouse breast cancer model resulted in approximately 50% tumor growth inhibition versus approximately 35% with anti-PD1 antibody and was well tolerated. ...
MDS-UPDRS Total score improved significantly for patients treated with ANAVEX®2-73 high oral once-daily dose compared to placebo. The improvement is clinically relevant, corresponding to a relative improvement of 18.9% over 14 weeks. ...
About SOLOSEC SOLOSEC (secnidazole) 2 g oral granules is the first and only single-dose oral prescription approved to treat both bacterial vaginosis (BV), a common vaginal infection, in adult women and trichomoniasis, a sexually transmitted infection, in adults.1-4 SOLOSEC is designed to be easy to take and one oral ...
In response to the updated WHO guidelines, Professor Vincent Marconi — Professor of Medicine and Global Health at the Emory School of Medicine and leader of the COV-BARRIER trial — commented: “The WHO guidelines reflect the best available evidence, derived from properly conducted multi-centre randomised-controlled phase 3 studies. As baricitinib is oral, ...
Initial pre-purchase of 10 million doses of oral vaccines with a potential deal for further orders worth hundreds of millions of dollars Prospective patient population of approximately 660 million throughout the Association of Southeast Asian Nations Oramed Pharmaceuticals Inc. ...
Study demonstrated a favorable risk/benefit profile over a three-year period, with safety comparable to AURORA 1, and sustained efficacy - Topline results show sustained meaningful reductions in proteinuria compared to mycophenolate mofetil (MMF) and low-dose oral corticosteroids alone, the active study control - Similar to the active control, the ...
The subjects received their first dose of either AB-2004 or placebo at CNS Healthcare in Orlando, FL and Optimal Clinical Trials in Auckland, New Zealand, respectively. ...
Patients who completed 12 months of treatment in the Phase 3 AURORA 1 study were eligible to enroll in the AURORA 2 continuation study with the same randomized treatment of voclosporin at 23.7 mg twice daily or placebo, in combination with mycophenolate mofetil (MMF) at 1 g twice daily with either no or low-dose oral steroids, for an additional 24 months. A total ...
Formulated as a powder that can be mixed with food, AB-2004 offers convenient oral dosing for the ASD community. About the AB-2004 Phase 2b Trial The Phase 2b trial is a global, randomized, double-blind, placebo-controlled study evaluating the efficacy, safety, and tolerability of AB-2004 in children aged 13 to 17 who have been diagnosed with ASD. The study will ...